LL-37 vs KPV

Evidence-based comparison · Updated 2026

Summary

LL-37 and KPV are both research-only peptides with anti-inflammatory properties, but they serve distinct primary roles. LL-37 is better suited for research into antimicrobial defense, wound healing, and broad innate immune modulation, while KPV is more targeted toward intestinal inflammation and gut-specific inflammatory conditions. Choose LL-37 for infection-related or wound-healing contexts; choose KPV for gut inflammation research such as IBD or IBS.

Side-by-Side Comparison

	LL-37	KPV
Evidence	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data
Regulatory	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits	+Broad-spectrum antimicrobial effects +Modulates immune response +Promotes wound healing +Anti-inflammatory properties +May combat biofilms	+Strong anti-inflammatory effects +Gut healing properties +Reduces inflammatory cytokines +May help IBD and IBS +Wound healing support
Dosage	5-10 mg mg — 2-3x weekly	500-1000 mcg mcg — 1-2x daily
Route	Subcutaneous, Intramuscular	Subcutaneous, Oral
Category	Immune & Inflammatory Modulation	Immune & Inflammatory Modulation

Full research page

LL-37 →

Full research page

KPV →

Which Should You Choose?

LL-37 operates as a membrane-disrupting antimicrobial agent and broad innate immune activator, while KPV works through melanocortin receptor signaling to selectively suppress pro-inflammatory cytokines, making their mechanisms largely non-overlapping despite both having anti-inflammatory properties.

Choose LL-37 when:

+Research focus involves direct antimicrobial activity against bacteria, fungi, or biofilms
+The study context requires broad innate immune modulation including neutrophil recruitment and antigen presentation
+Wound healing research where both antimicrobial protection and tissue repair signaling are relevant

Choose KPV when:

+Research focus is specifically on intestinal or mucosal inflammation such as IBD or IBS
+The study requires targeted suppression of pro-inflammatory cytokines with a favorable side effect profile
+Research involves regulatory T cell differentiation or melanocortin receptor pathway modulation

Stacking LL-37 and KPV is not a commonly documented research protocol, though their non-overlapping mechanisms, antimicrobial and immune activation for LL-37 versus cytokine suppression for KPV, suggest theoretical complementarity in models involving infected or inflamed tissue.

Frequently Asked Questions

Can LL-37 and KPV be studied together in inflammatory gut models?⌄

There is currently no published research examining the combination of LL-37 and KPV in intestinal inflammation models. In principle, LL-37 could address microbial dysbiosis and mucosal immune signaling, while KPV targets cytokine-driven inflammation through melanocortin receptors. These mechanisms do not appear to conflict, but co-administration has not been validated in preclinical research and should be approached with caution.

Which peptide shows faster effects in wound healing research, LL-37 or KPV?⌄

LL-37 has a more direct and well-characterized role in wound healing, acting on formyl peptide receptor-like 1 to promote keratinocyte migration, angiogenesis, and neutrophil recruitment. KPV supports wound healing primarily through its anti-inflammatory effects rather than direct tissue repair signaling. Based on available preclinical data, LL-37 is the more studied candidate for wound healing endpoints specifically.

How do the anti-inflammatory mechanisms of LL-37 and KPV differ in practical research terms?⌄

LL-37 modulates inflammation as a secondary function to its primary antimicrobial role, operating through innate immune receptor activation and cytokine regulation in a broader, less selective manner. KPV, by contrast, acts specifically through MC3R and MC4R melanocortin receptors to suppress pro-inflammatory cytokine production and promote regulatory T cell differentiation, making it a more targeted anti-inflammatory agent. Researchers focused purely on inflammation suppression may find KPV's mechanism more precise.

Do LL-37 and KPV target the same cytokine pathways?⌄

Both peptides can influence pro-inflammatory cytokine production, but through distinct pathways. LL-37 modulates cytokines primarily via innate immune receptor activation, including effects on NF-kB and MAPK signaling downstream of FPRL1. KPV suppresses cytokine production through melanocortin receptor signaling, which operates via cAMP-mediated pathways. The upstream triggers and receptor systems involved are different, meaning overlap in cytokine outcomes does not imply redundancy in mechanism.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500 mots c vs semaglutide dsip vs melanotan ii retatrutide vs tirzepatide cjc 1295 vs ipamorelin